Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Early in 2012 Mary Ann Liebert, Inc. publishers will launch Disruptive Science and Technology, a bimonthly peer-reviewed journal that will publish game-changing research that has the potential to significantly improve human health, well-being, and productivity. The journal will present new and innovative results, essential data, cutting-edge discoveries, thorough syntheses and analyses, and publish out-of-the-box concepts.


During this week’s podcast, Dr. Alan Russell, founding director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh and editor in chief of Disruptive Science and Technology, talks about the need for such a journal. He discusses the key journal topics and describes how the journal’s articles will exemplify "game-changing" research.

Alan Russell (Ph.D. in Biological Chemistry, 1987, Imperial College of Science and Technology, University of London) is the Highmark Distinguished Professor in the Institute for Complex and Engineered Systems at Carnegie Mellon University. He is also the executive director of the Pittsburgh Tissue Engineering Initiative and the director of the National Tissue Engineering Center.

Dr. Russell was the founding director of the McGowan Institute for Regenerative Medicine, jointly established by the University of Pittsburgh School of Medicine and UPMC Health System as a center of expertise and education in therapies that reestablish tissue and organ function. The McGowan Institute is a center for research and clinical work in tissue engineering, adult-derived stem cell research and cellular therapies, biosurgery, and artificial and biohybrid organ devices. He was also founding president of the 3,000-member Tissue Engineering and Regenerative Medicine International Society.

He has given more than 250 national and international invited lectures. He holds 14 patents and has 23 patents pending.



  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »